Platelet and haemorheological markers in 'high risk' hypertensives are improved by tighter blood pressure control and cardiovascular risk management: A substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)

Journal of Internal Medicine

Volumn 255, Issue 1, 2004, Pages 59-67

  Spencer, C G C ^a   Gurney, D ^a   Felmeden, D C ^a   Blann, A D ^a   Beevers, D G ^a   Lip, G Y H ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Fibrinogen; Hypertension; Plasma viscosity; Rheological indices; Soluble P selectin; Von Willebrand factor

Indexed keywords

CHOLESTEROL; FIBRINOGEN; PADGEM PROTEIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTERY ENDOTHELIUM; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD RHEOLOGY; CARDIOVASCULAR RISK; CAROTID ARTERY INJURY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FIBRINOGEN BLOOD LEVEL; FOLLOW UP; HEMATOCRIT; HIGH RISK POPULATION; HUMAN; HYPERTENSION; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTCOMES RESEARCH; PLASMA VISCOSITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RISK MANAGEMENT; SCANDINAVIA; THROMBOCYTE COUNT;

ANTICHOLESTEREMIC AGENTS; BIOLOGICAL MARKERS; BLOOD CELL COUNT; BLOOD CIRCULATION; BLOOD PLATELETS; BLOOD PRESSURE; BLOOD VISCOSITY; CHOLESTEROL; DOUBLE-BLIND METHOD; FEMALE; FIBRINOGEN; FOLLOW-UP STUDIES; HEMATOCRIT; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; P-SELECTIN; PROSPECTIVE STUDIES; RISK FACTORS; VON WILLEBRAND FACTOR;

EID: 1642540207     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0954-6820.2003.01246.x     Document Type: Article

References (41)

1. MacMahon S, Peto R, Cutler J et al. Blood pressure stroke and coronary heart disease: part I, prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765-74.
2. Collins R, Peto R, MacMahon S et al. Blood pressure stroke and coronary heart disease: part 2 short term reductions in blood pressure: overview of randomised drug trials in their epidemological context. Lancet 1990; 335: 827-38.
3. Wood D, Durrington P, Poulter N, Mclnnes G, Rees A, Wray R. Joint British Recommendations on the Prevention of Coronary Heart Disease in Clinical Practice. Heart 1998: 80 (S2): S14-16.
4. Jager A, van Hinsbergh VWM, Kostense PJ et al. von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects. Arterioscler Thromb Vasc Biol 1999; 19: 3071-8.
5. Blann AD, Faragher EB, McCollum CN. Increased soluble P-selectin following myocardial infarction: a new marker for progression of atherosclerosis. Blood Coag Fibrinol 1997; 8: 383-90.
6. Maresca G, Di Blasio A, Marchioli R, Di Minno G. Measuring plasma fibrinogen to predict stroke and myocardial infarction. Arteriocler Thromb Vasc Biol 1999; 19: 1368-77.
7. Koenig W, Sund M, Filipiak B, Doring A, Lowel H, Ernst E. Plasma viscosity and the risk of coronary heart disease. Arterioscler Thomb Vasc Biol 1998; 18: 768-72.
8. Sweetnam PM, Thomas HF, Yarnell JW, Beswick AD, Baker IA, Elwood PC. Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease. Eur Heart J 1996; 17: 1814-20.
9. Lip GYH, Blann AD. Does hypertension confer a prothrombotic state? Circulation 2000; 101: 218-20.
10. Islim IF, Bareford D, Beevers DG. A single (investigator)-blind randomised control trial comparing the effects of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension. Platelets 2001; 12: 274-8.
11. Li-Saw-Hee FL, Beevers DG, Lip GYH. Effect of antihypertensive therapy using enalapril or losartan on haemostatic markers in essential hypertension: a pilot prospective randomised double-blind parallel group trial. Int J Cardiol 2001; 78: 241-6.
12. Muravyov AV, Zaitsev LG, Muravyov AA, Yakusevich VV, Sirotkina AM. Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension. Clin Hemorheol Microcirc 1998; 18: 185-90.
13. Kiesewetter H, Birk A, Jung F, Radtke H. Effects of felodipine on the arterial blood pressure and fluidity of blood in patients with arterial hypertension who stage I. Clin Remorheol 1994; 14: 355-67.
14. Toth K, Kesmarky G, Vekasi J et al. Hemorheological and hemodynamic parameters in patients with essential hypertension and their modification by alpha-1 inhibitor drug treatment. Clin Hemorheol Microcirc 1999; 21: 209-16.
15. Haenni A, Lithell H. Urapidil treatment decreases plasma fibrinogen concentration in essential hypertension. Metabolism 1996; 45: 1221-9.
16. Fogari R, Zoppi A, Lazzari P et al. ACE inhibition but not angiotensin II antagonism reduces plasma fibrinogen and insulin resistance in overweight hypertensive patients. J Cardiovasc Pharmacol 1998; 32: 616-20.
17. Blann AD, Waite MA. von Willebrand Factor and soluble E-selectin in hypertension: influence of treatment and value in predicting the progression of atherosclerosis. Coron Artery Dis 1996; 7: 143-7.
18. Sever PS, Dahlof B, Poulter NR et al. Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. J Hypertens 2001; 19: 1139-47.
19. Spencer CGC, Beevers DG, Lip GYH. Haemorheological, endothelial and platelet function in subjects with hypertension: relationship to cardiovascular risk and influence of antihypertensive treatment. J Human Hypertens 2001; 15 (S1): S39-42.
20. Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol 1992; 45: 1101-9.
21. Danesh J, Collins R, Peto R, Lowe GDO. Haematocrit, viscosity, erythrocyte sedimentation rate: meta-analyses of prospective studies of coronary heart disease. Eur Heart J 2000; 21; 515-70.
22. Cirillo M, Laurenzi M, Trevisan M, Stamler J. Haematocrit, blood pressure and hypertension. Hypertension 1992; 20: 319-26.
23. Woodward M, Rumley A, Tunstall-Pedoe H, Lowe GDO. Associations of blood rheology and interleukin-6 with cardiovascular risk factors and prevalent cardiovascular disease. Br J Haematol 1999; 104: 246-57.
24. Koenig W, Sund M, Ernst E, Keil U, Rosenthal J, Hombach V. Association between plasma viscosity and blood pressure. Am J Hypertens 1991; 4: 529-36.
25. Phillips AN, Neaton JD, Cook DG, Grimm RH, Shaper AG. Leukocyte count and risk of major coronary heart disease events. Am J Epidemiol 1992; 136: 59-70.
26. Folsom AR, Peacock JM, Nieto FJ et al. Plasma fibrinogen and incident hypertension in the Atherosclerosis Risk In Communities (ARIC) Study. J Hypertens 1998; 16: 1579-83.
27. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-6.
28. Biegelsen ES, Loscalzo J. Endothelial function and atherosclerosis. Coron Artery Dis 1999; 10: 241-56.
29. Bridges AB, McAlpine HM, Pringle TH, McLaren M, Belch JJF. Endothelial dysfunction in acute myocardial infarction. Am Heart J 1993; 126: 451-2.
30. Meigs JB, Mittleman MA, Nathan DM et al. Hyperinsulinaemia, hyperglycaemia and impaired haemostasis: the Framingham Offspring Study. JAMA 2000; 283: 221-228.
31. Blann AD, Hopkins J, Winkles J, Wainwright AC. Plasma and serum von Willebrand factor antigen concentrations in connective tissue disorders. Ann Clin Biochem 1992; 29: 67-71.
32. Folsom AR, Wu KK, Rosamond WD, Sharrett RA, Chambless LE. Prospective study of hemostatic factors and incidence of coronary heart disease. Circulation 1997; 96: 1102-8.
33. Jansson J-H, Nilsson TK, Johnson O, von Willebrand Factor, tissue plasminogen activator, and dehydroepiandrosterone sulphate predict cardiovascular death in a 10 year follow up of survivors of acute myocardial infarction. Heart 1998; 80: 334-337.
34. Davies MJ, Thomas AC, Knapman PA, Hangarter JR. Intramyocardial platelet aggregation in patients with acute myocardial infarction suffering sudden ischaemic cardiac death. Circulation 1986; 73: 418-27.
35. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-9.
36. Blann AD, Lip GYH, Beevers DG, McCollum CN. Soluble P-selectin in atherosclerosis: a comparison with endothelial cell and platelet markers. Thromb Haemost 1997; 77: 1077-80.
37. Jilma B, Eichler HG, Vondrovec B et al. Effects of desmopressin on circulating P-selectin. Br J Haematol 1996; 93: 432-6.
38. Tarazi RC, Frohlich ED, Dustan HP. Plasma volume in men with essential hypertension. N Eng J Med 1968; 278: 762-5.
39. Faggiotto A, Paoletti R. Statins and blockers of the renin angiotensin system: Vascular protection beyond their primary mode of action. Hypertension 1999; 34: 987-96.
40. Koenig W, Sund M, Ernst E et al. Effects of felodipine ER and hydrochlorothiazide on blood rheology in essential hypertension - a randomised, double blind crossover study. J Intern Med 1991; 229: 533-8.
41. Tsuda Y, Satoh K, Kitadai M, Takahashi T, Izumi Y, Hosomi N. Effects of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia. Atherosclerosis 1996; 122: 225-33.